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Nicotinamide N-methyltransferase expression in
SH-SY5Y neuroblastoma and N27 mesencephalic
neurones induces changes in cell morphology
via ephrin-B2 and Akt signalling
MG Thomas1, M Saldanha1, RJ Mistry1, DT Dexter2, DB Ramsden3 and RB Parsons*,1
Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1) N-methylates nicotinamide to produce 1-methylnicotinamide (MeN). We
have previously shown that NNMT expression protected against neurotoxin-mediated cell death by increasing Complex I (CxI)
activity, resulting in increased ATP synthesis. This was mediated via protection of the NDUFS3 subunit of CxI from degradation
by increased MeN production. In the present study, we have investigated the effects of NNMT expression on neurone
morphology and differentiation. Expression of NNMT in SH-SY5Y human neuroblastoma and N27 rat mesencephalic
dopaminergic neurones increased neurite branching, synaptophysin expression and dopamine accumulation and release.
siRNA gene silencing of ephrin B2 (EFNB2), and inhibition of Akt phosphorylation using LY294002, demonstrated that their
sequential activation was responsible for the increases observed. Incubation of SH-SY5Y with increasing concentrations of MeN
also increased neurite branching, suggesting that the effects of NNMT may be mediated by MeN. NNMT had no significant effect
on the expression of phenotypic and post-mitotic markers, suggesting that NNMT is not involved in determining phenotypic fate
or differentiation status. These results demonstrate that NNMT expression regulates neurone morphology in vitro via the
sequential activation of the EFNB2 and Akt cellular signalling pathways.
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Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1)
catalyses the N-methylation of nicotinamide into 1-methylni-
cotinamide (MeN).1 In the brain, NNMT expression is
regionally distributed, occurring solely in neurones.2 NNMT
expression is elevated in numerous cancers, for example,
bladder, lung and gastrointestinal tract,3–5 and NNMT may
serve as a prognostic marker for these cancers.6,7 NNMT is
hepatoprotective in hepatitis and cirrhosis8 and protects
against free radicals in pulmonary smooth muscle cells in
chronic obstructive pulmonary disease.9
Using post mortem caudate nucleus and cerebella, we have
shown that the expression of NNMT is increased in
Parkinson’s disease (PD) brains.2,10 Stable expression of
NNMT in the SH-SY5Y human neuroblastoma cell line, which
has no endogenous expression of NNMT, at levels of activity
comparable with that in PD brain, protected against the
toxicity of the Complex I (CxI) inhibitors 1-methyl-4-phenyl-
pyridinium ion and rotenone.11 This protection was mediated
via increased CxI activity and ATP production. Maintenance of
CxI activity arose from protection of the 30 kDa subunit of CxI
(NDUFS3) from degradation induced by 1-methyl-4-phenyl-
pyridinium ion and rotenone. Thus increased NNMT expres-
sion may be a stress response of the neurone to the PD
pathogenic process.
Induction of NNMT in renal clear cell carcinoma (RCC) cells
activated matrix metalloproteinase-2, resulting in morpholo-
gical changes as part of tumour metastasis.12 Matrix
metalloproteinase-2, which is involved in synaptic remodelling
and synaptogenesis,13 is upregulated by Akt signalling, which
is activated by the expression of NNMT in RCC cells.12 Akt,
also known as protein kinase B, is a serine/threonine kinase
that belongs to the cAMP-dependant protein kinase A/G/C
superfamily and is at the centre of a myriad of cellular
activities, including growth, proliferation, energy metabolism
and migration.14–16 The Akt pathway is activated by PI3
kinases, which phosphorylates Akt on residues Ser-473 and
Thr-308, triggering downstream effects, including inhibition of
p53, reduced expression of the pro-apoptotic gene Bim
and increased translation of anti-apoptotic proteins.14,16 Akt
and phosphorylated Akt (AktPi) are neuroprotective.
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Enhanced Akt expression is neuroprotective against the
toxicity of 6-hydroxydopamine in PD models.15,20 The
abundance of AktPi is significantly reduced in the dopaminer-
gic neurones of the substantia nigra in PD patients,21 and the
neuroprotective effects of rasagiline are mediated via the
activation of Akt signalling.22
Akt phosphorylation is activated by the ephrin B receptor
(ephB),20,23 whose ligand ephrin B2 (EFNB2) is induced
alongside NNMT as a result of increased hedgehog signalling
in pancreatic cancer cells.24 EFNB2 regulates transcellular
communication via interaction with ephB3 and B4 receptors,
tyrosine kinases present on the post-synaptic termini of
adjacent target cells.25 In the brain, EFNB2/ephB receptor
signalling is involved in regulating neuronal and axonal
migration, synaptic formation, function and plasticity26–29 via
interaction with a number of pre- and post-synaptic targets.30
Activation of the phosphorylation of Akt by the ephB receptor
gives rise to morphological and functional changes such as
increased synaptic formation, regulation of neuronal plasti-
city29 and protection of SH-SY5Y cells against the toxicity of 6-
hydroxydopamine.20
From the above, it can be seen that increased NNMT
expression is a feature of rapidly dividing cancer cells and in
neurones as a response to stressful states, such as PD.
Therefore, we explored the effect of NNMT expression upon
neuronal morphology and differentiation using our SH-SY5Y
cell model of NNMT expression (S.NNMT.LP).11 In addition,
we have used a second cell line, N27–rat mesencephalic
dopaminergic neurones–to confirm our findings.
Results
NNMT expression increased neurite branching and the
presynaptic marker synaptophysin. To investigate the
effect of NNMT expression upon neurone morphology, we
used the S.NNMT.LP cell line, produced as part of our ongoing
studies by the stable transfection of SH-SY5Y with a plasmid
encoding NNMT C-terminally fused to the V5 epitope.11
A single NNMT mRNA transcript and a single NNMT-V5
protein of the correct molecular weight were expressed solely
in S.NNMT.LP cells (Supplementary Figures S1A and S1B).
Cell death was significantly lower in S.NNMT.LP compared
with SH-SY5Y cells (Supplementary Figure S1C).
NNMT expression has been shown to induce morphological
changes in RCC cells, so we hypothesised that NNMT-V5
expression may have a similar effect upon SH-SY5Y
morphology. Changes in SH-SY5Y morphology were deter-
mined using phase contrast and differential interference
contrast (DIC) microscopy. DIC imaging allowed easier
analysis of neurite branches compared with phase-contrast
images. Under phase-contrast microscopy, SH-SY5Y cells
appeared rounded and showed a basic neuronal morphology
(Supplementary Figure S2, top panels), with a limited number
of neurites, intercellular connections and neurite branching.
By contrast, S.NNMT.LP cells appeared more elongated
(Supplementary Figure S2B, bottom panels), with increases
in the number of neurites per cell and the degree of branching.
The number of intercellular connections also increased.
Quantification using image analysis demonstrated that
neurite length was lower in S.NNMT.LP compared with that
of SH-SY5Y cells (18% decrease, P¼ 0.0288; Figures 1a
and b). The number of neurites per cell was increased in
S.NNMT.LP compared with the number in SH-SY5Y cells
(11% increase, Po0.001; Figure 1b top right panel), and the
number of branches per neurite of S.NNMT.LP was signifi-
cantly higher than those of SH-SY5Y cells (71% increase,
P¼ 0.0164) (Figure 1b bottom left panel). In SH-SY5Y cells,
39.6% of neurites had no branching (Figure 1b bottom right
panel), 28.7% had 1 branch, 20.8% had either 2 or 3 branches,
and only 10.9% of neurites had Z4 branches. By contrast, in
S.NNMT.LP cells, only 19.2% of neurites had no branches,
19.7% had only one branch 41.5% had either 2 or 3 branches;
and a further 19.6% of neurites hadZ4 branches. Thus neurite
branching was increased significantly in S.NNMT.LP cells
compared with the parental SH-SY5Y cells.
We next investigated whether S.NNMT.LP demonstrated
an increase in the expression of the presynaptic marker
synaptophysin.31 Synaptophysin expression was detected as
a 38 kDa protein in both SH-SY5Y and S.NNMT.LP cell lines
(Figure 1c left panel). Expression of synaptophysin was
significantly increased in S.NNMT.LP compared with that
seen in SH-SY5Y cells (Figure 1c right panel, 41.4% increase,
P¼ 0.004, n¼ 4).
The effect of NNMT upon neurone morphology was also
investigated using N27 cells. Substantia nigra dopaminergic
neurones are derived from the mesencephalon,32 hence N27
cells closely mimic dopaminergic neurones of the substantia
nigra. Wild-type N27 cells expressed no NNMT mRNA
(Supplementary Figure S3). Transient transfection of N27
using the pNNMT.D plasmid11 resulted in robust NNMT-V5
expression (Figure 1d left panel). Synaptophysin expression
was undetectable in mock-transfected N27 cells, whereas
transient expression of NNMT-V5 resulted in robust synapto-
physin expression. Mock-transfected N27 cells demonstrated
a degree of neuronal morphology but with very few neurites
and no interneuronal connections (Figure 1d right panel). N27
cells expressing recombinant NNMT-V5 had significantly
more neuronal processes with the presence of a number of
interneuronal connections (Figure 1d right panel). These
results confirm that NNMT-V5 expression induced the
formation of neurites and the expression of synaptophysin in
dopaminergic mesencephalic neurones.
NNMT expression increased dopamine uptake and
release. Next, we investigated whether dopamine uptake
and release was increased by NNMT-V5 expression.
Dopamine accumulation was significantly increased in
S.NNMT.LP compared with SH-SY5Y cells (Figure 1e left
panel, 4.8-fold increase, P¼ 0.0154), with a corresponding
increase in dopamine release (Figure 1e middle panel,
7.3-fold increase, P¼ 0.0182). The percentage of the
dopamine pool released was not significantly different in
S.NNMT.LP compared with SH-SY5Y cells (Figure 1e right
panel). Taken together, these results show that NNMT-V5
expression in SH-SY5Y cells changed cellular morphology
and increased dopamine uptake and release.
The effects of NNMT expression were mediated via
activation of EFNB2/Akt signalling. The next step was to
elucidate the signalling pathway involved using S.NNMT.LP
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cells. The first candidate investigated was the EFNB2
signalling pathway. Both SH-SY5Y and S.NNMT.LP cell
lines expressed a single EFNB2 mRNA transcript. EFNB2
protein expression was detected as two bands of approxi-
mately 49 and 28 kDa (Figure 2a upper panel), correspond-
ing to the full-length and ectodomains of EFNB2,
respectively.33,34 EFNB2 mRNA expression was significantly
increased in S.NNMT.LP compared with that in SH-SY5Y
cells (189% increase, P¼ 0.0037, n¼ 4). Levels of both 49
and 28 kDa immunoreactive proteins was significantly higher
in S.NNMT.LP cells (Figure 2a bottom panel, 564% increase,
P¼ 0.0014 for 48 kDa protein, 612% increase, P¼ 0.0182
for 28 kDa protein, n¼ 3 for both).
We investigated whether there was increased Akt phos-
phorylation, as Akt is a downstream target of EFNB2. Both
total Akt (AktT) and AktPi were detected as a single band of
approximately 60 kDa in both SH-SY5Y and S.NNMT.LP
cells, demonstrating robust expression of both (Figure 2b
upper panel). AktT expression was not significantly different in
S.NNMT.LP cells compared with that observed in SH-SY5Y
(Figure 2b lower panel, 4.2% decrease, P¼ 0.5179, n¼ 3),
whereas AktPi was increased in the presence of NNMT-V5
(35% increase, P¼ 0.0044, n¼ 3). Accordingly, the AktPi:AktT
ratio increased in response to NNMT-V5 expression (41.3%
increase, P¼ 0.0248, n¼ 3).
Next we demonstrated that EFNB2 was responsible for the
increase in AktPi and synaptophysin expression we observed
in S.NNMT.LP cells (Figure 3a). Silencing of EFNB2 expres-
sion in S.NNMT.LP cells (S.NNMT.LPEFNB2-) resulted in a
significant decrease in EFNB2 compared with S.NNMT.LP
cells transfected with scrambled siRNA (S.NNMT.LPWT; data
not shown). Silencing of EFNB2 expression resulted
in a significant decrease in AktPi (81.9% decrease,
P¼ 0.0004, n¼ 4) and the AktPi:AktT ratio (77.7% decrease,
Po0.0001, n¼ 4), with no effect upon AktT (18.9%
decrease, P¼ 0.06, n¼ 4). Silencing of EFNB2 expression
significantly reduced synaptophysin expression (46.1%,
P¼ 0.0006, n¼ 4). Silencing of EFNB2 expression resulted
in a small yet significant reduction in the number of neurites
per S.NNMT.LPEFNB2 cell compared with that in
S.NNMT.LPWT (0.79±0.067 versus 0.7±0.06, 11% reduc-
tion, Po0.0001) (Figure 3b). Quantitative analysis of neurite
length demonstrated that average neurite length in
S.NNMT.LPEFNB2 cells was increased compared with that
of S.NNMT.LPWT cells (35% increase,P¼ 0.0005), with many
neurites being hyper-elongated in S.NNMT.LPEFNB2 cells.
Finally, we investigated whether the phosphorylation of Akt
was responsible for increased synaptophysin expression.
Incubation of S.NNMT.LP cells with 50mM LY294002
decreased AktPi (50% decrease, P¼ 0.0034, n¼ 4), the
Figure 1 Expression of NNMT-V5 increased neurite branching and increased both synaptophysin expression and dopamine uptake and release. (a) DIC microscopic
images of SH-SY5Y and S.NNMT.LP. Neurites of S.NNMT.LP cells appeared to have more branches than SH-SY5Y neurites. Arrows indicate points of neurite branching.
Bar¼ 50mm. (b) Quantitative image analysis of DIC microscopic images. Average neurite length was significantly lower in S.NNMT.LP cells compared with SH-SY5Y. The
number of neurites per cell and the number of neurite branches was significantly higher in S.NNMT.LP cells. The distribution of branches per neurite was shifted towards
neurites having more branches in S.NNMT.LP cells. Error bars represent S.E.M. (c) Quantitative western blot analysis of synaptophysin expression in SH-SY5Y and
S.NNMT.LP cells. Synaptophysin expression was significantly increased in S.NNMT.LP cells. Error bars represent S.D. (d) Effect of transient expression of NNMT-V5 in N27
cells upon synaptophysin expression and neuronal morphology. Both NNMT-V5 and synaptophysin were detected only in N27 cells transiently transfected with pNNMT-V5.
NNMT-V5-expressing N27 cells demonstrated neurites (arrowed), which were absent in mock-transfected N27 cells. Bar¼ 50mm. (e) Dopamine accumulation and release in
SH-SY5Y and S.NNMT.LP cells. Dopamine accumulation (left) and Kþ -evoked dopamine release (middle) were significantly increased in S.NNMT.LP cells. The proportion of
the dopamine pool released upon Kþ stimulation (right panel) did not alter upon NNMT expression. Error bars represent S.D. NS¼ not significant
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AktPi:AktT ratio (46.3% decrease, P¼ 0.0052, n¼ 4) and
synaptophysin expression (56.3% decrease, P¼ 0.001,
n¼ 4) (Figure 3c). These results demonstrate that the effects
of NNMT-V5 expression upon SH-SY5Y cells were mediated
via the sequential activation of the EFNB2 and Akt signalling
pathways.
MeN replicated the effects of NNMT expression upon
SH-SY5Y neurite branching. We next determined whether
MeN, the metabolic product of NNMT, replicated the effects
of NNMT-V5 upon SH-SY5Y morphology using DIC micro-
scopy (Figure 4a). The amount of neurite branching
appeared to be higher in SH-SY5Y cells incubated with
MeN compared with untreated cells. The length of neuritic
processes did not significantly increase with increasing MeN
concentration (Figure 4b top left panel, 26.6±14.7mm in
untreated cells, compared with 30.1±20.6, 30.7±18.7 and
31.4±17.7 mm for 0.25, 0.5 and 1 mM MeN, respectively).
The number of neuritic processes per cell incubated in 1 mM
MeN increased by 10% compared with untreated cells
(Figure 4b top right panel, 0.834±0.002 versus
0.918±0.016, Po0.001). The degree of neurite branching
increased significantly in the presence of all concentrations
of MeN (Figure 4b bottom left panel). In untreated cells, there
were an average of 1.3±0.1 branches per neurite, which
increased to 2.9±0.2 in cells incubated with 1 mM MeN, an
increase of 124% (Po0.001). In all, 39% of neurite
processes had no branching, with a further 26% only having
one branch; only 5% of neurite processes had Z4 branches
(Figure 4b bottom right panel). This distribution shifted with
increasing MeN concentration, with 19% of neuritic pro-
cesses having Z4 branches in cells cultured in the presence
of both 0.25 mM and 0.5 mM MeN and 33% of neuritic
processes having Z4 branches in cells incubated in the
presence of 1 mM MeN.
NNMT reduced cholinergic phenotype but did not induce
terminal differentiation. In light of the increased dopamine
uptake and release induced by NNMT-V5 expression, we
investigated whether NNMT-V5 expression was involved in
SH-SY5Y differentiation using western blotting analysis of
various pan- and cell-specific neuronal markers using mouse
brain homogenate as a positive control (Figure 5). The
cholinergic marker Choline acetyltransferase (ChAT) was
expressed as a B70 kDa protein in both SH-SY5Y and
S.NNMT.LP cells and as aB72 kDa protein in mouse brain,
which is in accord with published reports.35,36 ChAT
expression was significantly lower in S.NNMT.LP cells
(66% reduction, P¼ 0.0066, n¼ 4). The serotonergic marker
tryptophan hydroxylase was expressed in SH-SY5Y,
S.NNMT.LP and mouse brain as a B56 kDa protein and
was unchanged by the expression of NNMT-V5 (7.1%
decrease, P¼ 0.3515, n¼ 4). The dopaminergic/noradrener-
gic marker tyrosine hydroxylase (TH) was expressed in
mouse brain as a B56 kDa protein and was undetected in
both SH-SY5Y and S.NNMT.LP cells. The post-mitotic
marker neuronal nuclei/FOX-3 (NeuN) was expressed in
SH-SY5Y, S.NNMT.LP and mouse brain as a double band of
B40–45 kDa protein as previously described.37 NeuN
expression was unchanged by the expression of NNMT-V5
Figure 2 NNMT-V5 expression activated the EFNB2/Akt cell signalling pathway. (a) Quantitative western blot analysis of EFNB2 expression in SH-SY5Y and S.NNMT.LP
cells. EFNB2 was detected as two bands of 49 and 28 kDa, corresponding to the full-length and cleaved forms, respectively. The expression levels of both were significantly
increased in S.NNMT.LP. (b) Quantitative analysis of AktT and AktPi expression in SH-SY5Y and S.NNMT.LP cells. The expression of AktPi and the AktPi:AktT ratio were
significantly increased in S.NNMT.LP, whereas the expression of AktT was unchanged. Error bars represent S.D. For both the panels, white bars¼ SH-SY5Y, black
bars¼ S.NNMT.LP
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(12.9% decrease, P¼ 0.2934, n¼ 4). Therefore, NNMT
expression reduced cholinergic phenotype but did not induce
dopaminergic/noradrenergic, serotonergic or terminal
differentiation.
Discussion
In this study, we show that NNMT expression increased the
number of neurites per cell, the number of branches per
neurite, the expression of the presynaptic marker synapto-
physin and the uptake and release of dopamine in SH-SY5Y
stably expressing NNMT-V5 (S.NNMT.LP). The effects upon
neurite formation and synaptophysin expression were also
repeated in N27 cells transiently expressing NNMT-V5. These
changes were shown to be brought about via the induction of
the EFNB2 and Akt cell signalling pathways, in that the
expression of NNMT was shown to activate these pathways,
whereas blockage of the pathways using (1) siRNA gene
silencing of EFNB2 and (2) inhibition of Akt phosphorylation
using LY294002 abolished the effects of NNMT-V5
expression. We also showed that the effects of NNMT-V5
expression upon neurite branching were replicated by the
addition of MeN.
Although SH-SY5Y cells are widely used in neurodegen-
erative disease research, their suitability for such studies is
controversial.38 SH-SY5Y are a tumour-derived pan-neuronal
cell line maintained in continuous culture, which require
terminal differentiation in order to phenotypically and mor-
phologically resemble true neurones. Using various differ-
entiation protocols, a number of neuronal phenotypes can be
produced.39–41 Although a tumour-derived cell line, it is
apparent from their robust expression of synaptophysin and
ability to accumulate and release dopamine that undifferen-
tiated SH-SY5Y cells do possess neuronal characteristics,
which make them useful for studies such as ours. SH-SY5Y
cells do not express NNMT, a fact we exploited in studies on
the effects of NNMT expression.11 Thus, the combination of
SH-SY5Y and S.NNMT.LP cells is an ideal model for
investigating the molecular pathways underlying the cellular
effects of NNMT. We also confirmed key experimental results
Figure 3 The sequential activation of the EFNB2 and Akt signalling pathways mediated the effects of NNMT-V5 expression in S.NNMT.LP cells. (a) Quantitative western
blotting analysis of the effect of EFNB2 gene silencing upon AktPi, AktT and synaptophysin expression. esiRNA silencing of EFNB2 expression significantly reduced AktPi,
AktPi:AktT and synaptophysin protein expression and had no effect upon AktT expression. Error bars represent S.D. (b) Quantitative image analysis of S.NNMT.LP cells.
esiRNA silencing of EFNB2 expression significantly altered neurite morphology (highlighted by arrows). Average neurite length was significantly higher in S.NNMT.LP cells in
which EFNB2 expression had been silenced. Error bars represent S.E.M. Bar¼ 50mm. (c) Quantitative western blotting analysis of the effect of the Akt phosphorylation
inhibitor LY294002 upon AktPi, AktT and synaptophysin expression. Incubation of S.NNMT.LP with LY294002 significantly reduced AktPi and synaptophysin expression and
had no effect upon AktT expression. Error bars represent S.D. For all panels, **Po0.01, ***Po0.001, NS¼ not significant, black bars¼ SH-SY5Y, white bars¼ S.NNMT.LP,
Syp¼ synaptophysin
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(changes in cellular morphology and synaptophysin expres-
sion) using N27 cells, an immortalised rat mesencephalic
neuronal cell line which expresses TH.42 Although also a cell
line maintained in continuous culture, N27 were produced by
the immortalisation of dopaminergic neurones derived from
embryonic day 12 rat mesencephalon using the SV40 large T
antigen.43,44 Such a paradigm allows us to negate the
possibility that the morphological effects observed arose as
a consequence of the tumourigenic nature of SH-SY5Y cells.
The most significant result of our study is that, in both
SH-SY5Y and N27 cells, expression of NNMT induced
changes in morphology via the sequential activation of the
EFNB2 and Akt signalling pathways. NNMT did not induce
terminal differentiation as evidenced by the lack of change in
the expression of the post-mitotic marker NeuN and the
continued replication of both S.NNMT.LP and transiently
transfected N27 cells. Also, NNMT does not appear to have
a major role in determining dopaminergic phenotypic fate,
demonstrated by both the lack of change in TH expression and
the dopaminergic phenotype of N27 cells, which do not
express NNMT. The activation of the EFNB2 and Akt signalling
pathways has been shown to induce morphological changes,
such as neuronal and axonal migration;27,29 thus the ability of
NNMT to activate EFNB2 and Akt signalling elevates NNMT
from historically being considered to be a component of Phase
II metabolism to regulating fundamental cell signalling path-
ways involved in neuronal development and survival.
It should be noted that, due to the pan-neuronal nature of
the cell lines used, the effects that we observe in this study
may not be replicated in terminally differentiated, non-dividing
neurones in vivo. However, if these results were to be
replicated, they would provide further evidence that the
increased NNMT expression that we have observed in PD
patients2,10 may not be part of the pathogenic process but
instead may be a stress response. However, enhanced
NNMT expression may be toxic in vivo in a manner that
cannot be observed using our in vitromodels. A small number
of studies have suggested that MeN is toxic towards
Figure 4 Incubation of SH-SY5Y with MeN increased neurite branching. (a) DIC microscopic images. Increasing concentrations of MeN appeared to increase the number
of neurite branches (arrows). Numbers in images represent concentration of MeN. Bar¼ 50mm. (b) Quantitative image analysis. Increasing concentrations of MeN had no
significant effect upon neurite length. By contrast, the the average number of neurites per cell and the number of neurite branches increased with increasing concentration of
MeN. Analysis of the population distribution of neurite branching showed that there was an increase in the number of neurite branches with increasing MeN concentration.
Error bars represent S.E.M. *Po0.05, **Po0.01, ***Po0.001, NS¼ not significant
Figure 5 NNMT-V5 expression decreased ChAT expression but had no effect upon final phenotype nor terminal differentiation. (a) Western blotting analysis of neuronal
markers. The phenotypic markers ChAT (cholinergic) and tryptophan hydroxylase (TrpH; serotonergic), along with the post-mitotic marker NeuN, were all detected as either
single bands (phenotypic markers) or as a double band (NeuN), whereas by contrast the dopaminergic marker TH was not detected in either SH-SY5Y or S.NNMT.LP cells.
(b) Quantitative densitometric analysis. The expression level of ChAT was significantly reduced in S.NNMT.LP, whereas that of TrpH, TH and NeuN were unaltered. Error bars
represent S.D. **Po0.01, NS¼ not significant
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neurones, using supraphysiological concentrations of
MeN,45–47 which are unlikely to be achieved even under
conditions of high NNMT expression. It is also possible that
NNMT may deleteriously affect pyridine nucleotide produc-
tion, but although we have previously shown that NNMT
expression reduced pyridine nucleotide synthesis, this had no
deleterious effect upon SH-SY5Y cell survival.11 Finally,
NNMT may potentially increase the production of methylated
tetrahydroisoquinolines and b-carbolines, endogenously pro-
duced compounds which inhibit CxI;48 however, as yet there is
no direct experimental evidence that NNMT is responsible for
the production of such compounds.
Materials and Methods
Unless otherwise stated, all materials were obtained from Sigma-Aldrich (Poole,
Dorset, UK) and were of the highest purity available. Male C57BL/6 mice were
obtained from the Biological Services Unit, King’s College London, London, UK from
which brain homogenate was prepared as previously described.2
Cell culture incubations. SH-SY5Y human neuroblastoma and S.NNMT.LP
cells (SH-SY5Y stably expressing NNMT produced as part of our ongoing studies)
were cultured as previously described.11 Recombinant NNMT (NNMT-V5) expression
and reduced S.NNMT.LP cell death compared with SH-SY5Y were confirmed as
previously described.11 For all experiments, SH-SY5Y cells at passage 19–22 and
S.NNMT.LP cells at passage number 7–9 (which correlates approximately with
passage 22–24 for SH-SY5Y) were used. In order to facilitate the investigation of the
effect of NNMT upon cell morphology and differentiation, both SH-SY5Y and
S.NNMT.LP cells were used in their undifferentiated state. N27 rat mesencephalic
dopaminergic neurones were cultured in AQMedia (Sigma, Poole, UK) supplemented
with 10% FBS, 2 mM glutamine and 100 U/ml penicillin/streptomycin.
Cell morphology analysis. SH-SY5Y and S.NNMT.LP cell morphology
was quantitatively analysed by DIC microscopy at 37 1C using a Zeiss AxioPlan 2
microscope (Carl Zeiss, Welwyn Garden City, UK) with a  40 objective lens,
combined with image analysis involving three measures of cellular morphology:
neurites per cell, neurite length, and the number of neurite branches. SH-SY5Y
and S.NNMT.LP cells were incubated on poly-L-lysine-coated glass microscopy
slides overnight, after which they were mounted in media under a coverslip. Image
analysis was performed using Adobe Photoshop CS2 (Adobe Systems, San Jose,
CA, USA) on seven independent images for each cell line. The total number of
cells counted was 184 for SH-SY5Y and 294 for S.NNMT.LP. Only neurites
415mm in length were considered as true neuritic processes and as such
counted. The number of neuritic processes per image was counted, normalised for
the number of nuclei present in the image and expressed as neuritic processes
per cell±S.E.M. The total number of neuritic processes counted was 132 for
SH-SY5Y and 198 for S.NNMT.LP. The lengths of these neurites were measured
and expressed as the average neuritic process length in mm±S.E.M. The number
of branches of each neurite included in the above analyses was counted and
expressed as number of branches per neurite±S.E.M. The population distribution
of the number of neurite branches per neurite was also calculated and expressed
as a percentage of neurites.
The effect of MeN upon SH-SY5Y cell morphology was also quantitatively
assessed using DIC. Cells were incubated as above for 24 h in media supplemented
with 0, 0.25, 0.5 and 1 mM MeN. Five unique images were analysed for each
incubation condition with the following total number of cells per incubation condition
counted: 184 (untreated), 143 (0.25 mM MeN), 183 (0.5 mM MeN), and 146 (1 mM
MeN). The total number of neuritic processes counted per incubation condition were
132 (untreated), 120 (0.25 mM MeN), 127 (0.5 mM MeN), and 131 (1 mM MeN).
Transient expression of NNMT in N27 cells. N27 cells were seeded at
a density of 75 000 cells/ml into the wells of a six-well plate and allowed to grow
until approximately 75% confluent. Cells were transiently transfected using the
pNNMT-D plasmid, which encodes NNMT C-terminally fused with the V5
epitope.11 After 48 h, recombinant NNMT-V5 expression was detected using
western blotting. Cells were imaged under phase-contrast microscopy using a
Canon D30 digital SLR camera mounted to an Axiovert C40 microscope (Zeiss).
[3H]-Dopamine accumulation and release. The uptake and subse-
quent accumulation of [3H]-dopamine by SH-SY5Y and S.NNMT.LP cells were
measured using the method of Lam et al.49 Specific dopamine uptake by
dopamine transporters was differentiated from non-specific dopamine uptake by
incubating identical samples in Krebs–Hepes buffer supplemented with 10 mM
nomifensine.50 After accumulation, the cells were washed thrice with Krebs/
HEPES for 15 min each and placed directly in ice. Cells were lysed using
phosphate-buffered saline supplemented with 1% (v/v) Triton X-100 for 20 min,
after which the homogenate was transferred into microcentrifuge tubes and
centrifuged briefly to remove particulate material. [3H]-Dopamine was measured in
the samples by mixing the homogenate 1 : 3 with Ultima Gold XR
scintillation cocktail and counted using scintillation spectroscopy (Beckman, High
Wycombe, UK). Further samples were assayed for protein concentration, and [3H]-
dopamine accumulation was calculated and expressed as nmoles dopamine/mg
protein/min±S.D.
Dopamine release from cells was stimulated using 50 mM potassium as
previously described.51 After stimulation for 5 min, the cells were placed
immediately in ice. The stimulation buffer was transferred without delay into
microcentrifuge tubes and centrifuged briefly to pellet any particulate material and
[3H]-dopamine counts were measured as described above. Further samples were
assayed for protein concentration and stimulated [3H]-dopamine release was
calculated and expressed as nmoles dopamine released/mg protein/min±S.D.
Additionally, the fraction of the total dopamine pool released was calculated and
expressed as a percentage of total dopamine pool released±S.D.
Reverse transcriptase PCR detection of NNMT expression.
mRNA was isolated from SH-SY5Y and N27 cells and expression of NNMT
mRNA was assessed using RT-PCR as described previously.11
Quantitative PCR analysis of EFNB2 mRNA expression. The
expression of EFNB2 mRNA was quantified in SH-SY5Y and S.NNMT.LP cells
using real-time quantitative PCR as previously described,11 using mRNA primers
and the appropriate Universal Probe Library probes as internal quantification
probe (Roche, Burgess Hill, UK) as outlined in Table 1. The housekeeping genes
b-actin and glyceraldehyde-3-phosphate dehydrogenase (Table 1) were used to
normalise mRNA expression. Results were calculated using the DDCt method and
expressed as a percentage of expression compared with SH-SY5Y cells±S.D.,
with EFNB2 mRNA in SH-SY5Y cells assigned an expression level of 100%. The
presence of single bands in each sample was subsequently confirmed using DNA
gel electrophoresis.
Quantitative western blot analysis of protein expression. The
expression levels of recombinant NNMT (NNMT-V5), EFNB2, synaptophysin,
AktT protein, TH, tryptophan hydroxylase, ChAT, NeuN and AktPi were quantified
using quantitative western blotting.11 Proteins were detected as outlined in
Table 2, and proteins were visualised using electrochemiluminescent detection.
To normalise for protein concentration, membranes were stripped using Restore
Western Stripping Reagent (Fisher Scientific, Loughborough, UK) and reprobed
for b-tubulin as outlined in Table 2. Images were digitally captured, band
intensities were quantified using densitometric analysis using the GeneTools
image analysis software (Syngene, Cambridge, UK) and normalised for b-tubulin
expression. Protein expression was calculated and expressed as a percentage of
the intensity observed in control cells±S.D. Synaptophysin and NNMT-V5
expression levels in N27 cells were not quantified. Additionally, Akt
phosphorylation was calculated by dividing the AktPi by the AktT intensity to
produce the AktPi:AktT ratio, which was subsequently expressed as a percentage
of AktPi:AktT observed in control cells±S.D.
siRNA-mediated silencing of EFNB2 expression. EFNB2 expres-
sion was silenced in S.NNMT.LP using MISSION EFNB2 esiRNA (Invitrogen,
Paisley, UK). S.NNMT.LP cells were plated at a density of 75 000 cells/ml into the
wells of a six-well plate and allowed to settle overnight, at which point cells were
approximately 50% confluent. Cells were subsequently transfected with 1 nM of
either EFNB2 esiRNA or scrambled esiRNA for 72 h, after which EFNB2 silencing
was confirmed using RT-PCR using the same primers outlined in Table 1.
Synaptophysin, AktT and AktPi protein expression were assessed using
quantitative western blotting. Neurite length and the number of neurites per cell
were assessed using quantitative image analysis of five randomly chosen phase-
contrast microscopic images as described above and expressed as average length
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in mm±S.E.M. The number of cells counted was 136 for scrambled esiRNA-
treated and 135 for EFNB2 esiRNA-treated cells.
Inhibition of Akt phosphorylation using LY294002. S.NNMT.LP
cells were seeded at a density of 75 000 cells/ml and allowed to grow until
approximately 75% confluent. Cells were incubated for 60 min in the presence or
absence of 50mM LY294002, after which the cells were lysed and AktT, AktPi and
synaptophysin expression were detected using western blotting.
Statistical analyses. All statistical analyses comprised comparison between
SH-SY5Y and S.NNMT.LP using Student’s t-test with Welch correction. The
exception was the comparison of the effect of MeN upon SH-SY5Y morphology,
which comprised one-way ANOVA with Tukey’s post hoc comparisons. For all
analyses, Po0.05 was taken as significant.
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